Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01814319 · ClinicalTrials.gov registry record · Phase 2
Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure
A Phase 2 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01814319 is a Phase 2 study that has completed, run by University of Cincinnati. The registered enrollment target is 20 participants.
The verdict
NCT01814319, a Phase 2 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Probenecid is an FDA approved drug for the treatment gout and hyperuricemia. It has been used safely in humans for decades for this and other indications. The investigators have recently discovered that this drug can also stimulate other receptors in the heart and therefore improve its function. The hypothesis of this study is that probenecid can be used to improve the function of the heart and therefore the symptoms in patients with heart failure.
Interventions
- DRUG Placebo
- DRUG Probenecid 1 gr oral twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01814319
The ClinicalTrials.gov registry entry for NCT01814319 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01814319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01814319 about?
NCT01814319 is a clinical study titled "Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure". Probenecid is an FDA approved drug for the treatment gout and hyperuricemia. It has been used safely in humans for decades for this and other indications. The investigators have recently discovered that this drug can also stimulate other receptors in the heart and therefore improve its function. The...
What is the current status of trial NCT01814319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-03. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01814319?
The interventions under investigation include: Placebo (DRUG), Probenecid 1 gr oral twice daily (DRUG).
Who is sponsoring clinical trial NCT01814319?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.